Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024. In the quarter to June 2026, revenue grew 38.3%, EPS fell 294.7%, free cash flow grew 5.09% and total debt rose 40.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

28.07 1.31 −4.46%
Market cap
$6.9B
P/E
0.0×
Fwd P/E
−213×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 3 3
ROE
26.21% 25.23% (2.66%) (32.03%)
ROA
9.44% 8.97% (0.84%) (5.16%)
ROIC
7.79% 7.05% (2.86%) (11.38%)
Return on Tangible Assets
20.21% 19.01% (1.74%) (53.48%)
Average Days of Receivables
0.00 5.00 23.05 53.13
Free Cash Flow per Share
0.59 0.33 0.35 0.36
Free Cash Flow
133.90 73.96 79.71 83.03
Other line items

Show all line items

Columns are period end dates